Targeted therapy of gastrointestinal stromal tumours

Table 2 Current role of targeted therapy in gastrointestinal stromal tumours

Agent	Use	Dose	Duration
Imatinib	First line in metastatic GISTs[13-15]	400 mg once daily (oral)	Till progression or intolerance
	Progression on 400 mg[13-15]	400 mg twice daily (oral)	Till progression or intolerance
	Exon 9 mutation[13-15]	400 mg twice daily (oral)	Till progression or intolerance
	Adjuvant in high risk cases[37]	400 mg daily (oral)	3 yr
	Neoadjuvant setting[29,39,40]	400 mg daily (oral)	6-12 mo
Sunitinib	Second line in metastatic setting[21,24]	50 mg once daily for 4 wk every 6 wk (oral) or 37.5 mg once daily continuously (oral)	Till disease progression or intolerance
Regorafinib	Third line in metastatic setting[26]	160 mg once daily for 3 wk every 4 wk (oral)	Till disease progression or intolerance

GISTs: Gastrointestinal stromal tumours.